Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

COMPUGROUP MEDICAL SE & CO. KGAA

(COP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CompuGroup Medical : áMedicaláannounces medium-termátargets foráEBITDA-margináfor the first timeáand confirms 2021 guidance

09/14/2021 | 12:52pm EST
  • Adjusted EBITDA margin expected to increase to approximately 25 % in 2023 and to approximately 27 % in 2025
  • Organic revenue growth year-on-year of 5 % and more per year expected for the years 2021 through 2025
  • Annual guidance for 2021 confirmed
  • Digitization in the healthcare sector accelerates growth

CompuGroup Medical SE & Co. KGaA, one of the leading e-health providers in the world, announces medium-term targets for the development of the adjusted EBITDA-margin for the first time. The medium-term growth target of increasing group revenues year-on-year organically by 5 % and more per year from 2021 through 2025 had been published previously. In addition, the Managing Directors have now also adopted targets for the medium-term increase in adjusted EBITDA margin for the first time. Accordingly, CompuGroup Medical aims to increase the adjusted EBITDA margin to approximately 25 % in 2023 and to approximately 27 % in 2025. Further information on medium-term targets will be presented at the virtual Capital Markets Day tomorrow.

In light of the ongoing investment program announced in December 2020 to accelerate growth, the Managing Directors confirm the full year 2021 guidance. CompuGroup Medical expects revenues in 2021 to be in a range of EUR 1 billion and EUR 1.04 billion as well as adjusted EBITDA between EUR 210 million and EUR 230 million.

Digital transformation in healthcare accelerates growth

'Digitization is finally happening in healthcare, reinforced by the pandemic. Our customers' world is transforming rapidly. CompuGroup Medical is ideally positioned to support doctors, pharmacies, hospitals and other healthcare professionals on their path towards digitization', says CEO Dr. Dirk Wössner. 'Governments across Europe have realized the need to digitize and modernize the healthcare space, and the transformation is gaining speed. We are ready to capture this fantastic opportunity. Organic growth has already accelerated in the first half of this year, and we confirm our ambition to achieve an organic year-on-year revenue growth of 5 % and more per year from 2021 through 2025.'

CFO Michael Rauch adds: 'This year we have significantly stepped up our investments to accelerate our organic growth. At the same time, we are targeting a clear path towards increasing profitability post the investment phase we announced in December 2020. We expect to be back at former levels of profitability with an adjusted EBITDA margin of approximately 25 % in 2023 and to increase the level even further going forward with a target margin of approximately 27 % by 2025.'

Further information on the virtual Capital Markets Day 2021 will be available for download on the company website www.cgm.com/ir.

Forward-Looking Statements

This release contains 'forward-looking statements'. Forward-looking statements may differ significantly from future results and often in fact differ. All forward-looking statements reflect CompuGroup Medical SE & Co. KGaA's (CompuGroup Medical) current view on future events and are subject to risks relating to future events and other risks, uncertainties and assumptions regarding CompuGroup Medical's business, financial position, results of operations, liquidity, prospects, growth or strategy. Forward-looking statements should always be considered from the perspective of the date on which they are made. CompuGroup Medical as well as their affiliated companies expressly disclaim any obligation to update, review or adjust any forward-looking statements contained in this release as a result of new information, future developments or other reasons. Any responsibility for the future accuracy of the opinions expressed in this release or the actual occurrence of the forecast developments is expressly excluded.

Disclaimer

CompuGroup Medical SE published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 September 2021 16:51:08 UTC.


ę Publicnow 2021
All news about COMPUGROUP MEDICAL SE & CO. KGAA
11/25CompuGroup Medical To Launch $42 Million Share Buyback
MT
11/25COMPUGROUP MEDICAL SE & CO. KGAA : Release of a capital market information
EQ
11/25CompuGroup Medical SE & Co. KGaA adopts resolution on share buy-back program for up to ..
EQ
11/11COMPUGROUP MEDICAL : Gets a Buy rating from Berenberg
MD
11/09COMPUGROUP MEDICAL : Baader Bank remains a Sell rating
MD
11/08COMPUGROUP MEDICAL : Kepler Cheuvreux gives a Neutral rating
MD
11/04CompuGroup Medical SE & Co. KGaA Reports Earnings Results for the Third Quarter and Nin..
CI
11/04COMPUGROUP MEDICAL : Kepler Cheuvreux remains Neutral
MD
11/04COMPUGROUP MEDICAL : Gets a Buy rating from Warburg Research
MD
11/04COMPUGROUP MEDICAL : Baader Bank reaffirms its Sell rating
MD
More news
Analyst Recommendations on COMPUGROUP MEDICAL SE & CO. KGAA
More recommendations
Financials
Sales 2021 1 022 M 1 156 M 1 156 M
Net income 2021 80,6 M 91,2 M 91,2 M
Net Debt 2021 512 M 579 M 579 M
P/E ratio 2021 44,3x
Yield 2021 0,85%
Capitalization 3 520 M 3 981 M 3 980 M
EV / Sales 2021 3,94x
EV / Sales 2022 3,66x
Nbr of Employees 8 079
Free-Float 48,8%
Chart COMPUGROUP MEDICAL SE & CO. KGAA
Duration : Period :
CompuGroup Medical SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGROUP MEDICAL SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 66,75 €
Average target price 84,80 €
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Dirk W÷ssner Chairman-Management Board & CEO
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Sven Thomas MŘller Vice Chairman & Chief Information Officer
Ulrike Handel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
COMPUGROUP MEDICAL SE & CO. KGAA-15.08%3 981
ORACLE CORPORATION39.11%246 004
SAP SE6.44%152 226
SERVICENOW, INC.13.25%124 048
DOCUSIGN, INC.5.18%45 997
HUBSPOT, INC.93.13%37 503